Adaptimmune Therapeutics plc (ADAP)
|52 Week Range||3.37-10.93|
|1y Target Est||-|
|Debt / Equity||33.13%||Neutral|
Upgrades & Downgrades
Adaptimmune to Report Q2 2021 Financial Results and Business Update on Monday, August 9, 2021
PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 28, 2021 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report financial results and provide a business update for the second quarter e... ...
Why Adaptimmune Therapeutics Stock Sank in the First Half of 2021
The biotech's shares have definitely lost their shine in 2021. ...
The Motley Fool
Dollar General, HP, Johnson & Johnson and More Friday Afternoon Analyst Calls
With the trading day more than halfway over, the markets were moving higher going into the weekend. ...
24/7 Wall Street
Why Adaptimmune Therapeutics Crushed the Market Today
A key pipeline drug performs well in a mid-stage clinical trial. ...
The Motley Fool
Adaptimmune's Stock Trades Higher As TCR Therapy Shows Initial Durability In Soft Tissue Cancer Sett...
Adaptimmune Therapeutics plc (NASDAQ: ADAP) revealed initial data from its Phase 2 SPEARHEAD-1 trial evaluating afamitresgene autoleucel (afami-cel, formerly ADP-A2M4). Data will be presented at the American Society of Clinical Oncology (ASCO) congre... ...
Two Complete Responses and Response Rate of 41% for People with Synovial Sarcoma Reported at ASCO in...
- Data will support BLA filing for afamitresgene autoleucel next year - ...
Adaptimmune's HiT Program Can Potentially Kill Human Tumor Cells, Animal Study Shows
Adaptimmune Therapeutics plc (NASDAQ: ADAP) has reported first preclinical data from its HiT targeting mesothelin (a tumor-associated antigen), being co-developed with Astellas Pharma (OTCMKTS: ALPMF) The data were presented at the American Society f... ...
First Preclinical Data from Adaptimmune's Mesothelin HiT Program at ASGCT Demonstrate Antigen-specif...
- Preclinical data validate that human T-cells expressing a TCR targeting mesothelin, independent of HLA recognition, can kill human tumor cells - ...
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2021 Results - Earnings Call Transcri...
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q1 2021 Results - Earnings Call Transcript ...